Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

Robin L. Jones*, Daniela Katz, Elizabeth T. Loggers, Darin Davidson, Eve T. Rodler, Seth M. Pollack

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of durable clinical benefit with antiangiogenic agents in this disease. A retrospective search of patients treated at three sarcoma referral centers was performed to identify patients with advanced chondrosarcoma treated with antiangiogenic agents. The aim of this study was to evaluate the efficacy and safety of antiangiogenic agents in advanced chondrosarcoma. Ten patients were identified; seven with conventional, one each with clear cell, extraskeletal mesenchymal chondrosarcoma and extraskeletal myxoid chondrosarcoma. The median progression-free survival for patients with conventional and clear cell sarcoma was 22.6 months. Median overall survival has not been met. Antiangiogenic therapy was well tolerated in this series of patients. Our retrospective data suggest that antiangiogenic therapy can provide prolonged clinical benefit in advanced chondrosarcoma patients. Further prospective trials are required to precisely define the role of this class of agent in advanced chondrosarcoma.

Original languageEnglish (US)
Article number167
JournalMedical Oncology
Issue number10
StatePublished - Oct 1 2017
Externally publishedYes


  • Advanced/metastatic
  • Antiangiogenic
  • Chondrosarcoma
  • Pazopanib
  • Ramucirumab
  • Systemic therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma'. Together they form a unique fingerprint.

Cite this